Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker's blockbuster weight loss drug Wegovy and diabetes treatment Ozempic.
A federal judge in Texas late Thursday rejected a bid by compounding pharmacies to keep making copies of Ozempic and Wegovy while a legal challenge over the shortage of those drugs unfolds. That came in response to a February lawsuit from a compounding trade group against the Food and Drug Administration's determination that the active ingredient in those drugs, semaglutide, is no longer in shorter in the U.S.
Patients flocked to the cheaper copycats when Ozempic and Wegovy were in short supply over the last two years due to skyrocketing demand, or if they didn't have insurance coverage for the costly treatments.
During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. Many telehealth companies, such as Hims & Hers, also offered those copycats. But drugmakers and some health experts have pushed back against the practice because the FDA does not approve compounded drugs, which are essentially custom-made copies prescribed by a doctor to meet a specific patient's needs.
"We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage" of semaglutide is resolved, said Steve Benz, Novo Nordisk's corporate vice president, legal and U.S. general counsel, in a statement.
"Patient safety remains a top priority for Novo Nordisk and the extensive nationwide legal actions we have taken to protect Americans from the health risks posed by illegitimate 'semaglutide' drugs are working," he said, referring to the company's more than 100 lawsuits against compounding pharmacies and other entities across 32 states.
On Thursday, U.S. District Judge Mark Pittman specifically denied the Outsourcing Facilities Association's bid for a preliminary injunction that would have prevented the FDA from taking action against its members for making copies of semaglutide.
That decision upholds the FDA's previous determination that the semaglutide shortage in the U.S. is over and means the FDA can now immediately go after so-called 503A pharmacies that are making compounded versions of semaglutide according to individual prescriptions for a specific patient.
Those pharmacies are largely regulated by states rather than the FDA.
Those pharmacies make compounded drugs according to individual prescriptions for a specific patient and are largely regulated by states rather than the FDA.
The decision also means the FDA can start targeting federally regulated 503B pharmacies, which manufacture compounded drugs in bulk with or without prescriptions, after May 22. The agency's actions can include product seizures and warning letters to pharmacies.
The decision on Thursday follows another win for Novo Nordisk. A different federal judge in Texas earlier this week ruled in favor of the drugmaker against a 503A pharmacy, MediOak Pharmacy, permanently prohibiting the business from marketing or selling compounded semaglutide.
Novo Nordisk and Eli Lilly have aggressively cracked down on compounding pharmacies over the last two years as they benefit from the soaring popularity of their weight loss and diabetes drugs.
Eli Lilly has gone through a similar legal process with tirzepatide, the active ingredient in its weight loss drug Zepbound and diabetes treatment Mounjaro. The FDA declared the U.S. shortage of tirzepatide over last year, prompting the same compounding trade group to sue the FDA over the drug.
In March, a federal judge denied the compounding group's request for a preliminary injunction on the FDA's enforcement against its members for making copies of Mounjaro and Zepbound. The compounding group has appealed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
‘Unfathomable': Seth Rogen Torches Lawmakers Threatening Cuts to Medicaid
Lauren Miller Rogen was 22 years old, celebrating her graduation from college the first time she noticed something was happening to her mother, Adele. It was relatively minor: 'She repeated herself — she told a story a few times about a friend of hers,' Rogen says. But for Lauren, who had watched Adele care for her own parents as they slowly succumbed to Alzheimer's disease, it was the potential future that unnerved her. Within two years, Adele, a first-grade teacher, would be diagnosed with early-onset Alzheimer's at age 55. By that time, Lauren was living in Los Angeles, and dating her then-boyfriend, the actor Seth Rogen. When the couple married a few years later, Adele's condition had progressed to the point that it wasn't clear at their wedding if she even realized who Lauren was. 'She knew I was the bride — she kept calling me the bride,' Lauren recalled in Taking Care, a documentary the couple made to raise awareness about the challenges that families face while caring for a person with advancing dementia. The toll of caring for Adele was hardest on Lauren's father. 'There was a time early on, before we brought care in, where we were like, 'Oh, we're gonna lose him first.' This — caring for her — seemed like it's literally killing him,' she says. 'Without being able to afford outside help, I dread imagining what would have happened,' Lauren says. The couple went on to found a nonprofit, Hilarity for Charity, that disburses grants to offset the cost of caring for a person with dementia. 'Until we were part of the care system, we didn't realize how broken it was,' Seth says in a video they recorded on behalf of the organization Caring Across Generations, to raise alarms about the threat families face under a pair of proposals to slash health care programs for the poor and disabled that are being considered at the state and federal level, and encourage people to contact their legislators. He adds, 'Millions of low income families, families of people with disabilities, families that have older adults in them, are facing this struggle every day right now. And that is why it is so unfathomable that federal and state legislatures are making massive cuts to Medicaid as we speak.' 'We are cutting crucial services for people who are aging and disabled,' he explains. 'That means these people will be losing access or have less access to the health care they need, creating more out-of-pocket expenses and medical debt.' In Washington, President Donald Trump's 'Big Beautiful Bill,' which was recently approved by the Republican majority in the House of Representatives, would cut roughly $600 billion from Medicaid in order to help pay for a new round of tax cuts for the wealthy. The Trump tax bill is projected to kick over 10 million people off Medicaid, the government health insurance program for low-income and disabled Americans. The legislation would also limit so-called provider taxes, which states use to provide supplemental payments to hospitals, doctors, and other health care providers to help pay the costs of treating Medicaid patients. The bill would additionally impose a financial penalty on states, like California, that offer health coverage to undocumented immigrants. In California, the situation could be compounded by further cuts proposed by Governor Gavin Newsom (D) that would slash Medi-Cal, the state's Medicaid program. Roughly one quarter of the five million Americans with dementia rely on Medicaid, the country's largest payer of long-term care. Medicaid is a pillar for caregivers — some 12 percent of recipients are people who can't work because of their responsibilities caring for a family member. Their ability to access the program could be jeopardized by the Big Beautiful Bill, which would impose work requirements on all able-bodied adults under 65 in order to qualify for Medicaid. 'Almost everyone in this country knows or loves someone that relies on Medicaid, even if they don't rely on Medicaid themselves. And we have the power together,' Lauren says in the video. 'We need to reject any cuts or changes that would take more care away from families that need and deserve it,' Seth adds. 'At the state level and the federal level.' More from Rolling Stone Trump Continues Inflaming L.A. Protests: 'BRING IN THE TROOPS!!!' ABC News Suspends Journalist for Calling Stephen Miller and Trump 'World-Class Haters' Republicans Say They're Cool With Trump Deploying Troops Against Protesters Best of Rolling Stone The Useful Idiots New Guide to the Most Stoned Moments of the 2020 Presidential Campaign Anatomy of a Fake News Scandal The Radical Crusade of Mike Pence
Yahoo
21 minutes ago
- Yahoo
FDA Announces Recall of Over 20 Million Eggs After Salmonella Outbreak in 7 States
On June 6, 2025, the U.S. Food and Drug Administration (FDA) announced that August Egg Company of Hilmar, California, is recalling over 1,700,000 dozen brown cage-free and brown certified organic eggs, totaling over 20 million eggs. The recall was initiated in response to an ongoing investigation by the FDA and the Centers for Disease Control and Prevention (CDC) into a multistate outbreak of Salmonella that has sickened 79 people and resulted in 21 hospitalizations so far. While the eggs were produced by August Egg Company, they were sold under multiple brand names at restaurants and retailers. This recall includes eggs sold in 6-, 12-, and 18-count packs as well as larger restaurant boxes under the following brand names: Clover, First Street, Nulaid, O Organics, Marketside, Raley's, Simple Truth, Sun Harvest, and Sunnyside. The recalled eggs were distributed from Feb. 3, 2025, through May 6, 2025, to Walmart locations in nine states: Arizona, California, Illinois, Indiana, Nebraska, Nevada, New Mexico, Washington, and Wyoming, These eggs have "sell by" dates ranging from March 4, 2025, to June 4, 2025. The eggs were also distributed from Feb. 3, 2025, through May 15, 2025, to several retailers in California and Nevada, including Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raley's, Food 4 Less, and Ralphs. These eggs have "sell by" dates ranging from March 4, 2025, to June 19, 2025. At this time, the Salmonella outbreak investigation is ongoing, with illnesses reported in seven states: Arizona, California, Kentucky, Nebraska, Nevada, New Jersey, and Washington. The FDA is working to determine if the eggs were distributed to any other retailers in additional states. The recall may be updated as more information becomes available. You can identify the recalled eggs by checking the side of the carton. The recalled eggs feature a printed Julian Date on the side between '32' and '126' followed by a plant code number 'P-6562' or 'CA-5330' on the egg carton or package. The recalled eggs sold to consumers are packed in fiber or plastic cartons, with the above codes printed on one side of the carton. Here is a full list of the recalled eggs, along with their identifying information: Item Name Plant Number Carton UPC Clover Organic Large Brown 12 eggs P-6562 or CA-5330 070852010427 First Street Cage Free Large Brown Loose (1 case = 150 eggs) P-6562 or CA-5330 041512039638 Nulaid Medium Brown Cage Free 12 eggs P-6562 or CA-5330 071230021042 Nulaid Jumbo Brown Cage Free 12 eggs P-6562 or CA-5330 071230021011 O Organics Cage Free Large Brown 6 eggs P-6562 or CA-5330 079893401522 O Organics Large Brown 12 eggs P-6562 or CA-5330 079893401508 O Organics Large Brown 18 eggs P-6562 or CA-5330 079893401546 Marketside Organic Large Cage Free Brown 12 eggs P-6562 or CA-5330 681131122771 Marketside Organic Large Cage Free Brown 18 eggs P-6562 or CA-5330 681131122801 Marketside Large Cage Free Brown 12 eggs P-6562 or CA-5330 681131122764 Marketside Large Cage Free Brown 18 eggs P-6562 or CA-5330 681131122795 Raley's Large Cage Free Brown 12 eggs P-6562 or CA-5330 046567033310 Raley's Large Cage Free Brown 18 eggs P-6562 or CA-5330 046567040325 Raley's Organic Large Cage Free Brown 12 eggs P-6562 or CA-5330 046567028798 Raley's Organic Large Cage Free Brown 18 eggs P-6562 or CA-5330 046567040295 Simple Truth Medium Brown Cage Free 18 eggs P-6562 or CA-5330 011110099327 Simple Truth Large Brown Cage Free 18 eggs P-6562 or CA-5330 011110873743 Sun Harvest Organic Cage Free Large Brown 12 eggs P-6562 or CA-5330 041512131950 Sun Harvest Organic Cage Free Large Brown 18 eggs P-6562 or CA-5330 041512145162 Sunnyside Large Brown Cage Free 12 eggs P-6562 or CA-5330 717544211747 Sunnyside Large Brown Cage Free 18 eggs P-6562 or CA-5330 717544211754 Sunnyside Organic Cage Free Large Brown 12 eggs P-6562 or CA-5330 717544201441 Sunnyside Organic Cage Free Large Brown 18 eggs P-6562 or CA-5330 717544211761 Loose Small Brown Cage Free (1 box = 6 flats) (1 flat = 30 eggs) P-6562 or CA-5330 NA Loose Medium Brown Cage Free (1 box = 6 flats) (1 flat = 30 eggs) P-6562 or CA-5330 NA Loose Medium Brown Organic (1 box = 6 flats) (1 flat = 30 eggs) P-6562 or CA-5330 NA Loose Large Brown Organic (1 box = 6 flats) (1 flat = 30 eggs) P-6562 or CA-5330 NA Loose Jumbo Brown Cage Free (1 box = 5 flats) (1 flat = 20 eggs) P-6562 or CA-5330 NA Loose Jumbo Brown Organic (1 box = 5 flats) (1 flat = 20 eggs) P-6562 or CA-5330 NA You can also view photos of the labels on the FDA website. The recalled eggs are no longer in stores, but the FDA is concerned they may still be in consumers' homes. Per FDA guidance, check your refrigerators for the recalled brown cage-free and brown certified organic eggs. If you have the recalled eggs, throw them away or return them to the original place of purchase for a full refund. If you stored the eggs without their original packaging and can't tell if they are part of this outbreak, the FDA urges you to discard them out of an abundance of caution. Additionally, be sure to carefully clean and sanitize any surfaces that may have come in contact with the contaminated eggs. Further questions about this recall may be directed to August Egg Company at 1-800-710-2554, between 9 a.m. and 5 p.m. PT. If you believe you have already consumed the recalled eggs, you should monitor yourself for symptoms of a Salmonella infection. The most common symptoms include diarrhea, stomach cramps, dehydration, vomiting, and fever higher than 102°F—and, typically, symptoms begin between six hours and six days after eating the contaminated food. If you're experiencing any of those symptoms, contact your healthcare provider. While most individuals feel better after four to seven days, Salmonella can cause serious infections in children, older individuals, and those with weakened immune systems. To learn more about Salmonella, visit the CDC website. Read the original article on ALLRECIPES
Yahoo
22 minutes ago
- Yahoo
Big Data Can Make America Healthier. How to Do It Right
Credit - Ezra Bailey—Getty Images Big data can help make Americans healthier, and the Trump Administration has stated—in its recently released Make America Healthy Again report and elsewhere—that building a national big-data platform is one of its primary goals. As scientists who use large data sets to study health, we're excited about its potential and the willingness of the federal government to invest in it, particularly since big data has been underutilized in the U.S. compared with other developed countries—and since the number of ways it can be used grows nearly daily. It's a huge opportunity. But there are lots of concerns when assembling sensitive health data and combining it with other sensitive data, like credit scores, tax records, employment, educational records, and more. Some of those concerns with the Administration's plans have already surfaced. The Administration's first goal of assembling big data to studying autism has left some worried that if used inappropriately, such data could lead to harm, rather than help, for those with autism. Others worry that big data could be used to perform and justify shoddy research that supports predetermined conclusions without adhering to rigorous scientific methods—a concern reinforced by the discovery that the Make America Healthy Again report cited non-existent sources to support its claims. So how can we reap the benefits of big data while minimizing its risks? Here are some guiding principles: The health care system already possesses health data on millions of Americans. Medical records are now almost always digitized, permitting doctors' notes, medical imaging, laboratory tests, insurance claims, and more to be linked (in theory) across doctors' offices, hospitals, nursing homes, and any other place people receive care. However, data collected about a patient in one setting often doesn't get connected to data from other settings—making it hard for researchers to get a full picture of what, exactly, is happening to each of us within the larger health care system. Read More: Gun Injuries of All Kinds Go Up During Hunting Season The federal government also has data on us that can be connected to health care data to answer important questions. For example, comprehensive and detailed data on Americans' occupations linked with health, insurance, and other data could help shed more light on relationships between our work and our health—helping to better answer curious questions like why taxi drivers are less likely to die from Alzheimer's disease or why female physicians don't outlive their male colleagues. The first step of making big data more helpful is to simply link the data—which, while possible, is difficult to accomplish without centralized effort. Once linkages have been made, data can be anonymized so that those studying sensitive questions aren't privy to confidential information about specific individuals. In addition to governmental data, many other sources of data can provide insights into our health. For example, smartwatches not only have data on how our hearts are beating (e.g., they can identify abnormal heart rhythms like atrial fibrillation), but they can also identify subtle changes in mobility that might be predictive of early neuromuscular diseases like Parkinson's disease. Meanwhile, grocery stores have data on the foods we eat, and with increasing interest in how diet affects our lives, these data could be linked to detailed measures of health. Read More: Could the Shingles Vaccine Help Prevent Dementia? Similarly, social-media platforms possess data that can offer insights into changes in our mental health, and through large-scale analysis of online photos could even identify, in real time, early visible markers of disease. These are moonshots, of course, and whether we want to use data in this way is an open question. But the potential to improve health could be large. Creating a way for scientists to link outside data to existing government and health data—while responsibly maintaining individual anonymity after the linkage—could open many novel research opportunities. Keeping all of these data sources organized, secure, and accessible to scientists is a tall order. Researchers who use big data often dedicate substantial resources to finding the data they need, organizing it, and ensuring its accuracy; the better the database is maintained, the easier it is for researchers to actually perform their analyses. The secure online platform where Medicare and other government health care data are currently accessed has been described by researchers as 'tedious and prone to system errors' and in need of major improvements. Meanwhile, security concerns have led the government to stop letting researchers store the data on their own secure servers, the easiest and most cost-effective way to actually work with the data. Access to Medicare data by researchers has become prohibitively expensive, costing about $30,000 a year or more for a single user to work on one project using the online platform. Read More: Why We Can't Rely on Science Alone to Make Public Health Decisions Proposals to drastically cut medical research funding have been reported, and if passed, these research funding cuts will come at the cost of discoveries to improve health that will never be made. High-quality research of any kind requires investment, whether it's in a biology lab under a microscope or working with data on powerful computers. A new data platform is only as valuable as researchers' ability to access it in a functional and cost-effective way. Any roadmap to designing a national data platform that links together health care and other sensitive data must consider the many valid concerns about collecting data in the U.S., including privacy concerns and how data will be used. The Pew Research Center finds that large majorities of Americans say they are concerned about how the government uses data collected about them (71%), while also admitting that they have little to no understanding of what the government even does with such data (77%). Here are some strategies—in addition to many of the cybersecurity and privacy safeguards already in place—to both protect the data and help earn the public trust: Mistrust and unease with government data collection is readily traceable to historical abuse of Americans' data (as well as recent allegations of improper access), so it's not surprising that many are wary of the Trump Administration's plans. Ensuring data cannot be weaponized by the government against individuals is perhaps the single biggest barrier to creating a useful database, but it can be done. Those currently using federal health care data must already undergo training and comply with very high data-security standards. Misuse of the data—such as even attempting to figure out the identity of an anonymous individual in the data—or failure to protect patient privacy can lead to criminal penalties. A platform of sensitive data without well-delineated restrictions on who can use it and what they can use it for is a recipe for problems. Other ongoing efforts by the Administration to compile data under the vague goal of 'increasing government efficiency' have been met with pushback and lawsuits from organizations concerned about data being used against members of the public. Current use of federal health data also requires researchers to provide the government detailed plans to justify the use of specific data. This allows the government to ensure that no more data than is needed to answer the specific question is provided to researchers. Read More: Why Do Taxi Drivers Have a Lower Risk of Alzheimer's? Researchers must also obtain ethical approval from an Institutional Review Board prior to accessing and analyzing data, a second checkpoint. These boards, which exist in light of egregious failures of medical research ethics in the 20th century, help ensure that analyses are designed to minimize risk to patients—even if it is only their data, and not their bodies, at risk. Transparency into who is using this sensitive data and what exactly they are doing with it can engender trust between researchers and the American public. Just like researchers already do for clinical trials, those accessing the data platform should specify their plans in advance, and those plans should be easily and publicly available. Transparency around which data were accessed and what computer code was used to analyze it not only promotes trust, but such data- and code-sharing practices among researchers make it easier to appraise the quality of the work, identify mistakes, and root out misconduct. We can only assume that Americans' unease with governmental data use stems from knowledge that, as with all powerful tools, linked data has the potential to be used in potentially harmful ways. But when in the hands of qualified scientists using rigorous scientific methods and privacy safeguards, a robust real-world data platform like this could lead to new discoveries about how all of us can lead healthier lives. Contact us at letters@
